Merit Medical acquires Biolife for $120M

USA – Merit Medical Systems has acquired Biolife Delaware, a maker of hemostatic devices, for US$ 120 million.

The acquisition, announced Tuesday, includes StatSeal and WoundSeal—two products designed to stop bleeding quickly and effectively.

Merit expects the deal to generate around US$ 18 million in additional revenue in 2026. The move aligns with the company’s strategy of making strategic, tuck-in acquisitions that complement its current offerings.

StatSeal is a topical bleeding control device that uses a hydrophilic polymer and potassium ferrate to form a seal, reducing the need for frequent dressing changes.

In a clinical study involving 207 patients with catheter site bleeding, 99% of StatSeal dressings remained effective for seven days, compared to just 7% of dressings without it.

WoundSeal, an over-the-counter first aid product, consists of a powder that forms an instant scab when pressed onto a wound. It is marketed for use in treating minor domestic injuries.

Merit CEO Fred Lampropoulos said StatSeal and WoundSeal target an estimated US$ 350 million global market and are expected to deliver mid-teens revenue growth.

He added that Merit’s global reach and operational strength will help scale the products and boost market penetration. This acquisition continues Merit’s recent deal-making momentum.

In the past two years, the company has spent over US$ 450 million acquiring technologies including Cook Medical’s lead management portfolio (US$ 210M), Endogastric Solutions’ acid reflux device ($105M), dialysis catheter lines (US$ 132.5M), and surgical tools from Scholten Surgical Instruments (US$ 6M).

Analysts at Needham said the Biolife deal aligns with Merit’s ongoing strategy to expand into high-growth therapeutic markets. J.P. Morgan called the acquisition “an attractive addition” that enhances Merit’s ability to deliver innovative healthcare solutions.